KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $961.3 million.

  • BeOne Medicines' Cash from Financing Activities rose 749178.64% to $961.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $958.0 million, marking a year-over-year increase of 7577.28%. This contributed to the annual value of $193.4 million for FY2024, which is 5355.12% down from last year.
  • BeOne Medicines' Cash from Financing Activities amounted to $961.3 million in Q3 2025, which was up 749178.64% from $35.0 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Cash from Financing Activities registered a high of $3.3 billion during Q4 2021, and its lowest value of -$110.4 million during Q4 2022.
  • Its 5-year average for Cash from Financing Activities is $267.9 million, with a median of $35.0 million in 2025.
  • Per our database at Business Quant, BeOne Medicines' Cash from Financing Activities tumbled by 16385.62% in 2023 and then skyrocketed by 749178.64% in 2025.
  • Quarter analysis of 5 years shows BeOne Medicines' Cash from Financing Activities stood at $3.3 billion in 2021, then plummeted by 103.36% to -$110.4 million in 2022, then soared by 414.45% to $347.0 million in 2023, then tumbled by 101.3% to -$4.5 million in 2024, then soared by 21352.97% to $961.3 million in 2025.
  • Its Cash from Financing Activities was $961.3 million in Q3 2025, compared to $35.0 million in Q2 2025 and -$33.8 million in Q1 2025.